Status:
RECRUITING
Patients Derived Organoids in Ovarian Cancer
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Among cancer models, patients derived organoids (PDOs) best reproduce tumor's tissue architecture, intratumor heterogeneity and are able to mimic in vivo patients' drugs response. For these reasons, ...
Eligibility Criteria
Inclusion
- Preoperative clinical, serological and radiologic suspicion of International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or greater ovarian, fallopian tube, or primary peritoneal cancer;
- Histologic diagnoses of epithelial ovarian cancer at frozen section
- Age \>18 and years;
- Estimated life expectancy of at least 4 weeks;
- Performance status (PS) according to Eastern Cooperative Oncology Group (ECOG) \< 2
Exclusion
- Non-serous histology at frozen section;
- Patients with a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (\> 10 mg equivalent prednisone/daily) or any other form of immunosuppressive therapy within 7 days prior to the enrollment.
Key Trial Info
Start Date :
November 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 25 2025
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06085404
Start Date
November 25 2021
End Date
November 25 2025
Last Update
March 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Policlinico Universitario Agostino Gemelli
Roma, Italy